...
search icon
lxeo-img

Lexeo Therapeutics, Inc. Common Stock, Common Stock

LXEO

NMQ

$2.72

-$0.15

(-5.23%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$93.60M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
371.00K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.45 L
$19.5 H
$2.72

About Lexeo Therapeutics, Inc. Common Stock, Common Stock

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameLXEOSectorS&P500
1-Week Return-3.55%2.19%1.86%
1-Month Return-30.79%-5.18%6.39%
3-Month Return-4.9%-10.56%-0.73%
6-Month Return-67.66%-9.48%-2.29%
1-Year Return-83.05%-5.95%12.88%
3-Year Return-75.27%0.73%42.84%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue518.48K1.66M654.00K--[{"date":"2020-12-31","value":31.29,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":39.47,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-13.40K1.15M1.84M-[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":0.73,"profit":true},{"date":"2022-12-31","value":62.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit518.48K1.64M(491.00K)(1.84M)-[{"date":"2020-12-31","value":31.55,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-29.87,"profit":false},{"date":"2023-12-31","value":-112.13,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin100.00%99.19%(75.08%)(Infinity%)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.19,"profit":true},{"date":"2022-12-31","value":-75.08,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses5.11M52.29M61.16M66.67M105.77M[{"date":"2020-12-31","value":4.83,"profit":true},{"date":"2021-12-31","value":49.44,"profit":true},{"date":"2022-12-31","value":57.83,"profit":true},{"date":"2023-12-31","value":63.04,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(4.59M)(50.64M)(60.51M)(68.51M)(105.77M)[{"date":"2020-12-31","value":-458778800,"profit":false},{"date":"2021-12-31","value":-5063700000,"profit":false},{"date":"2022-12-31","value":-6050900000,"profit":false},{"date":"2023-12-31","value":-6851300000,"profit":false},{"date":"2024-12-31","value":-10576600000,"profit":false}]
Total Non-Operating Income/Expense(712.15K)30.00K2.47M4.78M14.88M[{"date":"2020-12-31","value":-4.79,"profit":false},{"date":"2021-12-31","value":0.2,"profit":true},{"date":"2022-12-31","value":16.58,"profit":true},{"date":"2023-12-31","value":32.14,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(5.15M)(50.62M)(59.28M)(66.39M)(98.33M)[{"date":"2020-12-31","value":-515278800,"profit":false},{"date":"2021-12-31","value":-5062200000,"profit":false},{"date":"2022-12-31","value":-5927700000,"profit":false},{"date":"2023-12-31","value":-6639400000,"profit":false},{"date":"2024-12-31","value":-9833300000,"profit":false}]
Income Taxes147.15K(155.00)89.00K(1.00)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-0.11,"profit":false},{"date":"2022-12-31","value":60.48,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(5.30M)(50.62M)(59.37M)(66.39M)-[{"date":"2020-12-31","value":-529993800,"profit":false},{"date":"2021-12-31","value":-5062184500,"profit":false},{"date":"2022-12-31","value":-5936600000,"profit":false},{"date":"2023-12-31","value":-6639399900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(5.15M)(50.62M)(59.28M)(66.39M)(98.33M)[{"date":"2020-12-31","value":-515278800,"profit":false},{"date":"2021-12-31","value":-5062200000,"profit":false},{"date":"2022-12-31","value":-5927700000,"profit":false},{"date":"2023-12-31","value":-6639400000,"profit":false},{"date":"2024-12-31","value":-9833300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(5.15M)(50.62M)(59.28M)(66.39M)(98.33M)[{"date":"2020-12-31","value":-515278800,"profit":false},{"date":"2021-12-31","value":-5062200000,"profit":false},{"date":"2022-12-31","value":-5927700000,"profit":false},{"date":"2023-12-31","value":-6639400000,"profit":false},{"date":"2024-12-31","value":-9833300000,"profit":false}]
EPS (Diluted)---(13.21)(3.08)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-1321,"profit":false},{"date":"2024-12-31","value":-308.45,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

LXEO
Cash Ratio 0.94
Current Ratio 3.42

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

LXEO
ROA (LTM) -42.89%
ROE (LTM) -80.65%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

LXEO
Debt Ratio Lower is generally better. Negative is bad. 0.30
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.70

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

LXEO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 1.08
Price/FCF NM
EV/R 416.34
EV/Ebitda NM

FAQs

What is Lexeo Therapeutics, Inc. Common Stock share price today?

Lexeo Therapeutics, Inc. Common Stock (LXEO) share price today is $2.72

Can Indians buy Lexeo Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Lexeo Therapeutics, Inc. Common Stock (LXEO) on Vested. To buy Lexeo Therapeutics, Inc. Common Stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LXEO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Lexeo Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Lexeo Therapeutics, Inc. Common Stock (LXEO) via the Vested app. You can start investing in Lexeo Therapeutics, Inc. Common Stock (LXEO) with a minimum investment of $1.

How to invest in Lexeo Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Lexeo Therapeutics, Inc. Common Stock (LXEO) via Vested in three simple steps:

  • Click on Sign Up or Invest in LXEO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Lexeo Therapeutics, Inc. Common Stock shares
What is Lexeo Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Lexeo Therapeutics, Inc. Common Stock (LXEO) is $19.5. The 52-week low price of Lexeo Therapeutics, Inc. Common Stock (LXEO) is $1.45.

What is Lexeo Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Lexeo Therapeutics, Inc. Common Stock (LXEO) is 1.08

What is the Market Cap of Lexeo Therapeutics, Inc. Common Stock?

The market capitalization of Lexeo Therapeutics, Inc. Common Stock (LXEO) is $93.60M

What is Lexeo Therapeutics, Inc. Common Stock’s stock symbol?

The stock symbol (or ticker) of Lexeo Therapeutics, Inc. Common Stock is LXEO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top